The best Side of HOIPIN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Principal demo goals were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis i